kxk016

Karen Knudsen, PhD

Contact Dr. Knudsen

233 S. 10th Street
Room 1008, Bluemle Life Sciences Building
Philadelphia, PA 19107

(215) 503-8574
(215) 923-1884 fax

Most Recent Peer-reviewed Publications

  1. Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer
  2. USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair
  3. The role of lineage plasticity in prostate cancer therapy resistance
  4. The AR-DNA repair axis: insights into prostate cancer aggressiveness
  5. Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'
  6. SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
  7. Pleiotropic impact of DNA-PK in cancer and implications for therapeutic strategies
  8. DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway
  9. Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset
  10. Cancer and the circadian clock
  11. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
  12. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy
  13. Rb1 heterogeneity in advanced metastatic castration-resistant prostate cancer
  14. DNA damage response in prostate cancer
  15. Novel Rb1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types
  16. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
  17. PARP-1 regulates DNA repair factor availability
  18. Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))
  19. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells
  20. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response